Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹6,029 Cr
P/E Ratio
22.37
P/B Ratio
2.55
Industry P/E
37.25
Debt to Equity
1.14
ROE
-6.88 %
ROCE
4.15 %
Div. Yield
0.38 %
Book Value
256.15
EPS
30.3
CFO
₹1,865.79 Cr
EBITDA
₹4,054.39 Cr
Net Profit
₹-4.19 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Strides Pharma
| -0.90 | -10.00 | 7.74 | -25.89 | 24.90 | 11.62 | -3.95 |
|
BSE Healthcare
| -7.27 | -1.01 | -0.76 | 19.87 | 19.29 | 22.12 | 9.77 |
|
BSE Small Cap
| -12.38 | 0.32 | -4.19 | 2.45 | 17.96 | 35.18 | 15.87 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Strides Pharma
| 0.79 | 85.58 | -21.74 | -49.28 | 142.87 | -22.35 | -43.87 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 425.60 | 6,920.24 | 25.22 | 12.5 | |
| 5,063.50 | 8,422.94 | 35.6 | 43.77 | |
| 680.85 | 6,674.72 | 75.6 | 4.01 | |
| 688.60 | 5,542.05 | 31.76 | 20.28 |
2 min read•By Jugal Harpalani
1 min read•By Research Desk
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The... company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India. Read more
Incorporated
1990
Chairman
Arun Kumar
Managing Director
Badree Komandur
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Strides Pharma Science Ltd stood at ₹ 5,990 Cr as on 31-Dec-24
The share price of Strides Pharma Science Ltd is ₹653.45 (NSE) and ₹654.15 (BSE) as of 25-Apr-2025 IST. Strides Pharma Science Ltd has given a return of 24.9% in the last 3 years.
Strides Pharma Science Ltd has a market capitalisation of ₹ 6,029 Cr as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Strides Pharma Science Ltd is 2.55 times as on 25-Apr-2025, a 50% discount to its peers’ median range of 5.15 times.
The P/E ratio of Strides Pharma Science Ltd is 22.37 times as on 25-Apr-2025, a 40% discount to its peers’ median range of 37.25 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Strides Pharma Science Ltd and enter the required number of quantities and click on buy to purchase the shares of Strides Pharma Science Ltd.
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
The prominent promoters of Strides Pharma Science Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
PRONOMZ VENTURES LLP |
19.58%
|
|
KARUNA BUSINESS SOLUTIONS LLP |
3.5%
|
|
ARUN KUMAR PILLAI |
2.24%
|
The chairman of the company is Arun Kumar, and the managing director is Badree Komandur.
The promoters of Strides Pharma Science Ltd have pledged 14.71% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,423
|
|
|
6,920
|
|
|
6,675
|
|
|
5,542
|
| Strides Pharma Science Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
12.68
|
|
Operating margin(%)
|
15.37
|
|
Net Margin(%)
|
7.34
|
|
Dividend yield(%)
|
0.38
|
Yes, TTM profit after tax of Strides Pharma Science Ltd was ₹270 Cr.
₹-27.60
(
